BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30558559)

  • 1. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.
    Alachkar N; Li J; Matar D; Vujjini V; Alasfar S; Tracy M; Reiser J; Wei C
    BMC Nephrol; 2018 Dec; 19(1):361. PubMed ID: 30558559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
    Staeck O; Slowinski T; Lieker I; Wu K; Rudolph B; Schmidt D; Brakemeier S; Neumayer HH; Wei C; Reiser J; Budde K; Halleck F; Khadzhynov D
    Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
    Alachkar N; Wei C; Arend LJ; Jackson AM; Racusen LC; Fornoni A; Burke G; Rabb H; Kakkad K; Reiser J; Estrella MM
    Transplantation; 2013 Oct; 96(7):649-56. PubMed ID: 23842190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.
    Morath C; Wei C; Macher-Goeppinger S; Schwenger V; Zeier M; Reiser J
    Am J Ther; 2013; 20(2):226-9. PubMed ID: 23466622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein A immunoadsorption cannot significantly remove the soluble receptor of urokinase from sera of patients with recurrent focal segmental glomerulosclerosis.
    Beaudreuil S; Zhang X; Kriaa F; Dantal J; Francois H; Vazquez A; Charpentier B; Lorenzo HK; Durrbach A
    Nephrol Dial Transplant; 2014 Feb; 29(2):458-63. PubMed ID: 24235085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.
    Franco Palacios CR; Lieske JC; Wadei HM; Rule AD; Fervenza FC; Voskoboev N; Garovic VD; Zand L; Stegall MD; Cosio FG; Amer H
    Transplantation; 2013 Aug; 96(4):394-9. PubMed ID: 23736353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
    Wei C; El Hindi S; Li J; Fornoni A; Goes N; Sageshima J; Maiguel D; Karumanchi SA; Yap HK; Saleem M; Zhang Q; Nikolic B; Chaudhuri A; Daftarian P; Salido E; Torres A; Salifu M; Sarwal MM; Schaefer F; Morath C; Schwenger V; Zeier M; Gupta V; Roth D; Rastaldi MP; Burke G; Ruiz P; Reiser J
    Nat Med; 2011 Jul; 17(8):952-60. PubMed ID: 21804539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful management of post-transplant focal segmental glomerulosclerosis with therapeutic plasma exchange and rituximab.
    Koutroutsos K; Charif R; Moran L; Moss J; Cook T; Roufosse C; Pusey C; Taube D; Loucaidou M
    Clin Exp Nephrol; 2019 May; 23(5):700-709. PubMed ID: 30637591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum suPAR in patients with FSGS: trash or treasure?
    Maas RJ; Deegens JK; Wetzels JF
    Pediatr Nephrol; 2013 Jul; 28(7):1041-8. PubMed ID: 23515666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
    Harel E; Shoji J; Abraham V; Miller L; Laszik Z; Thurison T; King A; Olshen A; Leung J; Szabo G; Hann B; Høyer-Hansen G; Craik CS; Vincenti F
    Clin Transplant; 2019 Mar; 33(3):e13487. PubMed ID: 30689221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Removal of focal segmental glomerulosclerosis (FSGS) factor suPAR using CytoSorb.
    Schenk H; Müller-Deile J; Schmitt R; Bräsen JH; Haller H; Schiffer M
    J Clin Apher; 2017 Dec; 32(6):444-452. PubMed ID: 28370393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis.
    Kumar J; Shatat IF; Skversky AL; Woroniecki RP; Del Rio M; Perelstein EM; Johnson VL; Mahesh S
    Pediatr Nephrol; 2013 Feb; 28(2):333-8. PubMed ID: 23052653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric focal segmental glomerulosclerosis: favorable transplantation outcome with plasma exchange.
    Fadel FI; Bazaraa HM; Abdel Mawla MA; Salah DM
    Ital J Pediatr; 2021 Dec; 47(1):236. PubMed ID: 34906202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.
    Winnicki W; Sunder-Plassmann G; Sengölge G; Handisurya A; Herkner H; Kornauth C; Bielesz B; Wagner L; Kikić Ž; Pajenda S; Reiter T; Schairer B; Schmidt A
    Sci Rep; 2019 Sep; 9(1):13783. PubMed ID: 31551522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
    Huang J; Liu G; Zhang YM; Cui Z; Wang F; Liu XJ; Chu R; Zhao MH
    BMC Med; 2014 May; 12():81. PubMed ID: 24884842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACTH Gel in Resistant Focal Segmental Glomerulosclerosis After Kidney Transplantation.
    Alhamad T; Manllo Dieck J; Younus U; Matar D; Alasfar S; Vujjini V; Wall D; Kanawati B; Reiser J; Brennan DC; Alachkar N
    Transplantation; 2019 Jan; 103(1):202-209. PubMed ID: 29894413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Preemptive Kidney Transplantation With Rituximab Induction in a Patient With Focal Segmental Glomerulosclerosis and Massive Nephrotic Syndrome: A Case Report.
    Kolonko A; Piecha G; Więcek A
    Transplant Proc; 2016 Nov; 48(9):3092-3094. PubMed ID: 27932154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab and Therapeutic Plasma Exchange in Recurrent Focal Segmental Glomerulosclerosis Postkidney Transplantation.
    Alasfar S; Matar D; Montgomery RA; Desai N; Lonze B; Vujjini V; Estrella MM; Manllo Dieck J; Khneizer G; Sever S; Reiser J; Alachkar N
    Transplantation; 2018 Mar; 102(3):e115-e120. PubMed ID: 29189487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor 1 antibodies associate with post-transplant focal segmental glomerulosclerosis and proteinuria.
    Abuzeineh M; Aala A; Alasfar S; Alachkar N
    BMC Nephrol; 2020 Jul; 21(1):253. PubMed ID: 32615995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Outcomes of Kidney Transplant Recipients With Primary Idiopathic Focal Segmental Glomerulosclerosis.
    Staeck O; Halleck F; Budde K; Khadzhynov D
    Transplant Proc; 2017 Dec; 49(10):2256-2259. PubMed ID: 29198656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.